SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
101,000
-1,800 (-1.75%)
At close: Oct 17, 2025
-1.75%
Market Cap7,909.64B
Revenue (ttm)620.28B
Net Income (ttm)255.99B
Shares Out78.31M
EPS (ttm)3,268.81
PE Ratio30.90
Forward PE40.22
Dividendn/a
Ex-Dividend Daten/a
Volume181,271
Average Volume171,524
Open101,700
Previous Close102,800
Day's Range100,700 - 102,700
52-Week Range86,900 - 129,800
Beta0.87
RSI41.68
Earnings DateNov 5, 2025

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 246
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.